Seer, Inc.
Seer (Nasdaq: SEER) develops and sells the Proteograph Product Suite, a research-use-only platform for deep, unbiased proteomic analysis at scale. Combining engineered nanoparticle consumables, automation instruments and data-analysis software, the system processes biological samples for mass spectrometry and measures… From the company’s description.
Over the twelve months to Jun 30, 2026, Seer, Inc. reported revenue of $14.22M, down 12.7% from a year earlier, and a net loss of $67.96M. Its operating margin was −498.2%, and operations used $43.38M in cash. In fiscal 2025, it reported revenue of $16.58M, up 17.0% from fiscal 2024, and a net loss of $73.60M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Seer, Inc. does
In the company’s own words
Seer (Nasdaq: SEER) develops and sells the Proteograph Product Suite, a research-use-only platform for deep, unbiased proteomic analysis at scale. Combining engineered nanoparticle consumables, automation instruments and data-analysis software, the system processes biological samples for mass spectrometry and measures proteins at peptide-level resolution, supporting protein variant analysis, biomarker discovery and integration of proteomic with genomic data. Its customers include academic institutions, biopharmaceutical companies, biobanks and clinical research organizations; Seer also serves researchers through service providers and international channel partners. Seer reports one business segment. The Proteograph portfolio includes the Proteograph ONE and DIRECT assays, the SP200 automation instrument and Proteograph Analysis Suite software; the company launched its commercial platform in 2021 and introduced ONE and SP200 in 2025. Since launch, it has served more than 190 customers in over 20 countries. In 2025, the SP200 workflow supports processing more than 1,000 samples per week, and the installed base spans academic, biopharma and contract research customers. Its website is https://seer.bio.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- REDWOOD CITY, CA
- Fiscal year end
- December
- CIK
- 1726445
- SIC
- 3826
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Seer, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Seer, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Seer, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Seer, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Seer, Inc.'s last four quarterly filings that the numbers alone won't show?”